Immediate Impact
3 from Science/Nature 55 standout
Citing Papers
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2024 Standout
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
2023 Standout
Works of Roger Qu being referenced
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria☆☆☆★
1999
Survival after relapse in childhood acute lymphoblastic leukemia
1998
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Roger Qu | 6 | 38 | 53 | 170 | 113 | 8 | 359 | |
| Dimitris Rizopoulos | 1 | 13 | 50 | 230 | 45 | 8 | 318 | |
| BC Wolf | 98 | 17 | 51 | 26 | 9 | 404 | ||
| M. S. Al-Adnani | 17 | 4 | 58 | 23 | 12 | 393 | ||
| A. Howland Hartley | 68 | 142 | 35 | 15 | 8 | 370 | ||
| Lipton Jm | 11 | 2 | 120 | 28 | 8 | 313 | ||
| José Miguel Couselo | 11 | 4 | 80 | 5 | 13 | 323 | ||
| E. Nikaï | 2 | 73 | 139 | 9 | 35 | 14 | 406 | |
| Janice L. Lookabaugh | 27 | 4 | 14 | 15 | 8 | 333 | ||
| Bernadette Heizel M. Reyes | 22 | 5 | 49 | 4 | 12 | 379 | ||
| Kim Murphy | 1 | 28 | 10 | 13 | 7 | 12 | 402 |
All Works
Loading papers...